Patent intelligence · WO
WO 2024243450
MÉTHODES DE TRAITEMENT UTILISANT DES CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-C-MET
MÉTHODES DE TRAITEMENT UTILISANT DES CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-C-MET
Patent details — WO 2024243450
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Nov 28, 2024
- Expiration
- Nov 23, 2044
- Applicant
- ABBVIE INC [US]
- CPC classes
- A61K 47/ 68 A I, A61K/476803, A61K/4768037, A61K/476851
Quick answer
WO 2024243450 (MÉTHODES DE TRAITEMENT UTILISANT DES CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-C-MET) is held by ABBVIE INC [US]. Status: granted. Granted Nov 28, 2024. Expires Nov 23, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ABBVIE INC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 47/ 68 A I, A61K/476803, A61K/4768037, A61K/476851, A61K/476855, A61K/476857
More from ABBVIE INC [US]
Related pharmaceutical patents in our USPTO index.
-
CA 3266054
COMPOSÉS DE N-MÉTHYL-4-(QUINOLIN-2-YL)PYRIDIN-2-AMINE
granted -
CA 3259391
POLYTHÉRAPIE ANTI-GARP-TGF-β1/PD-1
granted -
CA 3245150
COMBINAISONS AVEC UN ANTICORPS ANTI-CD39 HUMAIN, UN ANTICORPS ANTI-PD-1 HUMAIN ET UNE CHIMIOTHÉRAPIE CONTRE LE CANCER GASTRIQUE
granted -
US 2023174645
ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS
granted -
CA 3235096
METHODES DE TRAITEMENT DE L'ANEMIE CAUSEE PAR UNE MALADIE RENALE
granted -
CA 3207179
METHODES DE TRAITEMENT DE LA MALADIE DE CROHN ET DE LA COLITE ULCEREUSE
granted -
US 2022169620
SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS
granted
Frequently asked questions
What is US patent 2024243450?
WO 2024243450 (MÉTHODES DE TRAITEMENT UTILISANT DES CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-C-MET) is held by ABBVIE INC [US]. Status: granted. Granted Nov 28, 2024. Expires Nov 23, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2024243450?
ABBVIE INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 23 pharmaceutical patents for this assignee.
When does WO 2024243450 expire?
Our index shows an expiration date of Nov 23, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.